PubMed:17261113 / 155-511
Annnotations
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 21-27 | HP_0002018 | denotes | nausea |
| T2 | 32-40 | HP_0002013 | denotes | vomiting |
| T3 | 77-83 | HP_0002664 | denotes | cancer |
PubMed_Structured_Abstracts
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-356 | OBJECTIVE | denotes | Chemotherapy-induced nausea and vomiting (CINV) is a significant problem for cancer patients. Aprepitant, a novel NK-1 receptor antagonist, is approved for use with 5-HT3 antagonists and corticosteroids to prevent CINV associated with highly emetogenic chemotherapy. Nevertheless, the cost-effectiveness of standard aprepitant use has not been established. |